A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related …
Background Lipodystrophy (LD; peripheral lipoatrophy, central adiposity) hyperlipidaemia
and insulin resistance often complicate protease inhibitor-containing antiretroviral therapy.
Lipoatrophy and abdominal distension were observed in protease inhibitor-naive
nucleoside analogue reverse transcriptase inhibitor (NRTI) recipients with lactic acidaemia
and hepatic impairment, which are known NRTI-induced mitochondrial toxicities.
and insulin resistance often complicate protease inhibitor-containing antiretroviral therapy.
Lipoatrophy and abdominal distension were observed in protease inhibitor-naive
nucleoside analogue reverse transcriptase inhibitor (NRTI) recipients with lactic acidaemia
and hepatic impairment, which are known NRTI-induced mitochondrial toxicities.
Abstract
Background
Lipodystrophy (LD; peripheral lipoatrophy, central adiposity) hyperlipidaemia and insulin resistance often complicate protease inhibitor-containing antiretroviral therapy. Lipoatrophy and abdominal distension were observed in protease inhibitor-naive nucleoside analogue reverse transcriptase inhibitor (NRTI) recipients with lactic acidaemia and hepatic impairment, which are known NRTI-induced mitochondrial toxicities.
Lippincott Williams & Wilkins